Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

ARA-290 cycle length: what human studies ran

InvestigationalBLimited human data
Short answer: there is no established ARA-290 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. The 2012 sarcoidosis pilot dosed for 4 weeks 11; the 2013 sarcoidosis trial and the type 2 diabetes trial dosed for 28 days, with the diabetes trial following participants for a further month (56 days of observation in total) 12,13.
  2. The phase 2b sarcoidosis trial dosed for 28 consecutive days with the primary endpoint measured at day 28 3.
  3. The diabetic macular oedema trial dosed for 12 weeks (an 84-day period per the registry record), with outcomes measured from baseline to week 12 14.
  4. The healthy-volunteer study used a single administration with outcomes assessed one week later 15.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • ARA-290 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established ARA-290 cycle length?
No. Human studies administered ARA-290 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of ARA-290?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
ARA-290 dosing reference Full research page

References

  1. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin Proceedings of the National Academy of Sciences. 2008
  2. A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis (NCT02039687) ClinicalTrials.gov. 2015
  3. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain Investigative Ophthalmology & Visual Science. 2017
  4. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis Scientific Reports. 2017
  5. Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes Biochimica et Biophysica Acta — Molecular Basis of Disease. 2018
  6. ARA 290 for treatment of small fiber neuropathy in sarcoidosis Expert Opinion on Investigational Drugs. 2014
  7. The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy Volunteers (NCT02070783) ClinicalTrials.gov. 2013
  8. The Use of ARA290 for the Treatment of Diabetic Macular Oedema (NCT06626971) ClinicalTrials.gov. 2026
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026) FDA. 2026
  10. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  11. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study Mol Med. 2012
  12. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density Mol Med. 2013
  13. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes Mol Med. 2015
  14. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema (registry record NCT06626971) J Clin Med. 2020
  15. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action (registry record NCT02070783) Eur Neuropsychopharmacol. 2015
  16. ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes (NCT01933529), phase 2 registry record, status unknown ClinicalTrials.gov. 2015